NEXICLON XR Drug Patent Profile
✉ Email this page to a colleague
When do Nexiclon Xr patents expire, and what generic alternatives are available?
Nexiclon Xr is a drug marketed by Athena and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries.
The generic ingredient in NEXICLON XR is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nexiclon Xr
A generic version of NEXICLON XR was approved as clonidine by AVEVA on August 18th, 2009.
Summary for NEXICLON XR
| International Patents: | 21 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,434 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in NEXICLON XR? | NEXICLON XR excipients list |
| DailyMed Link: | NEXICLON XR at DailyMed |
Recent Clinical Trials for NEXICLON XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Louisville | Phase 4 |
| Arthroplasty Foundation, Inc. | Phase 4 |
| Children's Hospital of Pittsburgh | N/A |
Pharmacology for NEXICLON XR
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for NEXICLON XR
US Patents and Regulatory Information for NEXICLON XR
NEXICLON XR is protected by two US patents.
Patents protecting NEXICLON XR
Modified release formulations containing drug-ion exchange resin complexes
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Clonidine formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-001 | Dec 3, 2009 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-002 | Dec 3, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-001 | Dec 3, 2009 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-002 | Dec 3, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEXICLON XR
See the table below for patents covering NEXICLON XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Russian Federation | 2008140944 | КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА | ⤷ Try a Trial |
| Denmark | 2018160 | ⤷ Try a Trial | |
| Canada | 2645855 | FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES) | ⤷ Try a Trial |
| Denmark | 2428205 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
